How AI is transforming medical affairs through real-time scientific intelligence

How AI is transforming medical affairs through real-time scientific intelligence

Published: Sept 15th, 2026

A large oncology congress can release several thousand abstract titles inside a single embargo window. ClinicalTrials.gov now holds more than half a million registered studies. PubMed indexes on the order of 1.5 million new citations a year. Against that, a global medical team might have a handful of people covering an indication.

Access to scientific information stopped being the binding constraint some time ago. What remains scarce is the interval between something becoming known and the medical organization being able to act on it, and that is the specific problem AI in medical affairs is now being deployed against.

"Real time" means different clocks for different workflows

The phrase is only useful when tied to a workflow that already has a deadline attached.

Congress debriefs are typically expected within 24 to 48 hours of a presentation, while competitor data is still moving. Medical information teams usually work to service levels measured in one or two business days for standard requests, with shorter windows for urgent clinical queries. Field insights run on a much slower loop, often surfacing in quarterly medical strategy reviews, which means an observation made in February may not reach a decision until May. Guideline revisions, which for some oncology panels arrive several times a year, can invalidate parts of a scientific narrative between planning cycles.

Congress and literature surveillance: the tractable half

This is where current systems perform best, because the inputs are already semi-structured.

A capable pipeline clusters abstracts by mechanism, population or endpoint, extracts trial characteristics into consistent fields, resolves each abstract against its NCT identifier so prior presentations of the same study are recognized rather than double-counted, and links every extracted claim back to the source text. Deduplication against previously indexed conference material matters more than it sounds, since the same dataset often appears across three congresses in different cuts.

Interpretation stays human. A model can tell a team that a competitor reported a progression-free survival benefit in a second-line population. Whether that changes positioning is a medical judgment, and the useful gain is that reviewers spend their attention on the forty abstracts that matter rather than triaging three thousand.

Field insights: the unstructured half

Insight capture is harder, and it is where medical affairs insights software either earns its cost or quietly becomes another repository nobody reads.

The raw material is free text in CRM records, written in different languages, tagged against taxonomies that drift between affiliates. The same observation reported by twelve liaisons across four countries typically appears as twelve unrelated entries. Useful systems extract entities such as product, indication, evidence gap and competitor mention, cluster recurring themes, deduplicate across authors, and preserve the link back to each original interaction so a strategist can read the underlying notes rather than a paraphrase.

One design caution that pilots often miss: if insight capture becomes an organized, structured data collection exercise, safety reports arising from it may be classified as solicited rather than spontaneous under ICH E2D, which changes how they are processed and causality-assessed. That is a pharmacovigilance conversation to have before launch, not after.

Grounding, provenance, and the failure modes that actually occur

Retrieval-constrained generation over approved internal sources, meaning standard response documents, the label, dossiers and the publication library, behaves very differently from open-ended summarization. Provenance is available at the level of individual claims, and the dominant failure mode shifts from fabrication toward omission.

That matters because the errors generative models make in this domain are rarely obvious. Fabricated or mismatched citations are well documented. Subtler and more dangerous are population and endpoint substitutions: a subgroup result described as an intention-to-treat finding, a progression-free survival signal summarized as a survival benefit, a single-arm response rate presented with comparative framing. None of those look wrong to a non-specialist reviewer, and in a non-promotional function each is a compliance exposure rather than a typo. This is why generative AI in medical affairs works best as drafting support inside an existing medical review process.

The regulatory surface is wider than most pilots assume

Four obligations tend to be underestimated.

Safety reporting applies regardless of how an event is found. If a system reads interaction notes, medical information queries or public discourse and surfaces a suspected adverse event, expedited timelines apply, and detection needs a defined routing path into pharmacovigilance rather than an inbox.

Validation expectations do not disappear because a system is probabilistic. GAMP 5 Second Edition, published in 2022, added specific guidance on machine learning, and 21 CFR Part 11 audit trail and record controls still apply to systems supporting regulated activities. Continuously updated models raise a change control question that frozen ones do not.

FDA issued draft guidance in January 2025 on the use of AI to support regulatory decision-making for drug and biological products, built around a risk-based credibility assessment framework tied to a defined context of use. That framing is worth adopting internally even for activities outside its scope, and its current status should be checked since draft guidances move.

Publication workflows have their own rules. ICMJE recommendations are explicit that AI tools cannot be credited as authors and that their use must be disclosed, and Good Publication Practice 2022 governs the wider process.

Measure latency and accuracy, not output

Volume metrics flatter these tools. More defensible indicators: time from presentation or publication to internal briefing; medical information first-response time; the proportion of captured insights that reach a documented decision, with the date attached; duplicate rate within the insights repository; precision and recall of theme assignment measured against a human-coded sample; citation accuracy in AI-drafted summaries under periodic audit; and reviewer edit distance, which tends to reveal whether drafting support is saving effort or relocating it.

What to ask before buying medical affairs software

Which sources the system reads and how often they refresh. Whether provenance is available per claim or only per document. How conflicting evidence is represented rather than averaged away. What happens when provenance is missing. How model updates are change-controlled and revalidated. How adverse event routing is configured. Whether performance was evaluated prospectively on the buyer's own corpus rather than a vendor benchmark.

AI for medical affairs is best understood as compression of the interval between evidence and action. Teams that frame it that way tend to get durable gains in responsiveness. Teams that frame it as content generation tend to get volume, and a review burden to match.

Frequently Asked Questions